“What's different about REVEAL 1 and REVEAL 2 is they're identical across the design, except for the safety follow-up. So REVEAL 1 has a one year safety follow-up from the 36 week initial primary time point. REVEAL 2 has a one month follow-up. So it's much closer to finish from the primary endpoint. So we're very looking forward to having both REVEAL 1 full data set this year and REVEAL 2 in 2022. So that program is moving well, and we're very active and very excited.
the side effects of this current standard treatment besides the typical surgical related side effects is a reduction in capabilities to carry the babies post surgery. So, it's been well published that the surgery doubles the rate of spontaneous abortions and preterm birth.
So what VGX-3100 offers these patients is an opportunity to avoid surgery and treat the disease and the original cause of the disease, which is an HPV infection in the first place.
there's a strong market need for and want for a therapeutic like VGX-3100 and we'll demonstrate the efficacy through our pivotal trials, but we will also be able to present this strong case for the patients and the providers alike. So we think 3100 is a great immunotherapy candidate, and bringing in this new therapeutic option for the patient.
there are other diseases caused by the same viral infection in the other parts of the body, like the vulvar area for women and anal tracts for men and women, similar types of disease caused by the same viral infection but in different locations.
VGX-3100 has the potential to become a pan-anal genital immunotherapy those are caused by HPV-16 and 18.“
